Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review

Acute lymphoblastic leukemia (ALL) represents only 20 % of adult acute leukemias, while Lymphoblastic lymphoma is even rarer, accounting for 2 % of adult non-Hodgkin lymphomas. T-acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are neoplasms characterized by the presence of...

Full description

Saved in:
Bibliographic Details
Main Authors: Alaa Eldein Yahia, Ibrahim Motabi, Abdullah A. Alsakkaf, Kamal Alzahrani, Laila M. Alsuhaibani, Bilal Albtoosh, Abdullah Khaled AlBathi, Abdullah M. Alrajhi
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Leukemia Research Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048925000081
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849423115302469632
author Alaa Eldein Yahia
Ibrahim Motabi
Abdullah A. Alsakkaf
Kamal Alzahrani
Laila M. Alsuhaibani
Bilal Albtoosh
Abdullah Khaled AlBathi
Abdullah M. Alrajhi
author_facet Alaa Eldein Yahia
Ibrahim Motabi
Abdullah A. Alsakkaf
Kamal Alzahrani
Laila M. Alsuhaibani
Bilal Albtoosh
Abdullah Khaled AlBathi
Abdullah M. Alrajhi
author_sort Alaa Eldein Yahia
collection DOAJ
description Acute lymphoblastic leukemia (ALL) represents only 20 % of adult acute leukemias, while Lymphoblastic lymphoma is even rarer, accounting for 2 % of adult non-Hodgkin lymphomas. T-acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are neoplasms characterized by the presence of immature T-cell precursors or lymphoblasts. Relapsed T-ALL or LBL is associated with a very poor prognosis, necessitating the exploration of novel therapeutic approaches. This case report describes the use of Venetoclax in combination with Cladribine, Idarubicin, and Cytarabine (CLIA) as salvage therapy for relapsed T-ALL/T-LBL. The treatment regimen resulted in remission and negative minimal residual disease. However, it was accompanied by delayed count recovery, febrile neutropenia, and Central Line-Associated Bloodstream Infection. The management of central nervous system involvement was challenging due to low platelet counts requiring transfusion support. The findings highlight the need for further investigation into the efficacy and optimal therapeutic regimen for relapsed T-ALL/T-LBL. Additionally, the case emphasizes the importance of early salvage therapy and potentially consolidative hematopoietic stem cell transplantation for improved survival outcomes in relapsed T-ALL/T-LBL patients.
format Article
id doaj-art-42739a2a67e045a185948e16378b8512
institution Kabale University
issn 2213-0489
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Leukemia Research Reports
spelling doaj-art-42739a2a67e045a185948e16378b85122025-08-20T03:30:47ZengElsevierLeukemia Research Reports2213-04892025-01-012310050610.1016/j.lrr.2025.100506Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature reviewAlaa Eldein Yahia0Ibrahim Motabi1Abdullah A. Alsakkaf2Kamal Alzahrani3Laila M. Alsuhaibani4Bilal Albtoosh5Abdullah Khaled AlBathi6Abdullah M. Alrajhi7Department of Adult Hematology, King Fahad Medical City, Riyadh, Saudi ArabiaDepartment of Adult Hematology, King Fahad Medical City, Riyadh, Saudi ArabiaDepartment of Adult Hematology, King Fahad Medical City, Riyadh, Saudi ArabiaDepartment of Adult Hematology, King Fahad Medical City, Riyadh, Saudi ArabiaHematopathology Department, King Fahad Medical City, Riyadh, Saudi ArabiaDepartment of Nursing, King Fahad Medical City, Riyadh, Saudi ArabiaDepartment of Radiology, King Fahad Medical City, Riyadh, Saudi ArabiaClinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia; Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia; Corresponding author at: Clinical Pharmacy Department, King Fahad Medical City, Prince Abdulaziz Ibn Musaid S, FC4.2016, Riyadh, RH 12231, Saudi Arabia.Acute lymphoblastic leukemia (ALL) represents only 20 % of adult acute leukemias, while Lymphoblastic lymphoma is even rarer, accounting for 2 % of adult non-Hodgkin lymphomas. T-acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are neoplasms characterized by the presence of immature T-cell precursors or lymphoblasts. Relapsed T-ALL or LBL is associated with a very poor prognosis, necessitating the exploration of novel therapeutic approaches. This case report describes the use of Venetoclax in combination with Cladribine, Idarubicin, and Cytarabine (CLIA) as salvage therapy for relapsed T-ALL/T-LBL. The treatment regimen resulted in remission and negative minimal residual disease. However, it was accompanied by delayed count recovery, febrile neutropenia, and Central Line-Associated Bloodstream Infection. The management of central nervous system involvement was challenging due to low platelet counts requiring transfusion support. The findings highlight the need for further investigation into the efficacy and optimal therapeutic regimen for relapsed T-ALL/T-LBL. Additionally, the case emphasizes the importance of early salvage therapy and potentially consolidative hematopoietic stem cell transplantation for improved survival outcomes in relapsed T-ALL/T-LBL patients.http://www.sciencedirect.com/science/article/pii/S2213048925000081VenetoclaxCladribineIdarubicinCytarabineT-cell acute lymphoblastic lymphoma
spellingShingle Alaa Eldein Yahia
Ibrahim Motabi
Abdullah A. Alsakkaf
Kamal Alzahrani
Laila M. Alsuhaibani
Bilal Albtoosh
Abdullah Khaled AlBathi
Abdullah M. Alrajhi
Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
Leukemia Research Reports
Venetoclax
Cladribine
Idarubicin
Cytarabine
T-cell acute lymphoblastic lymphoma
title Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
title_full Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
title_fullStr Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
title_full_unstemmed Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
title_short Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
title_sort venetoclax combination with cladribine idarubicin cytarabine for relapsed t cell acute lymphoblastic leukemia lymphoblastic lymphoma treatment a case report and literature review
topic Venetoclax
Cladribine
Idarubicin
Cytarabine
T-cell acute lymphoblastic lymphoma
url http://www.sciencedirect.com/science/article/pii/S2213048925000081
work_keys_str_mv AT alaaeldeinyahia venetoclaxcombinationwithcladribineidarubicincytarabineforrelapsedtcellacutelymphoblasticleukemialymphoblasticlymphomatreatmentacasereportandliteraturereview
AT ibrahimmotabi venetoclaxcombinationwithcladribineidarubicincytarabineforrelapsedtcellacutelymphoblasticleukemialymphoblasticlymphomatreatmentacasereportandliteraturereview
AT abdullahaalsakkaf venetoclaxcombinationwithcladribineidarubicincytarabineforrelapsedtcellacutelymphoblasticleukemialymphoblasticlymphomatreatmentacasereportandliteraturereview
AT kamalalzahrani venetoclaxcombinationwithcladribineidarubicincytarabineforrelapsedtcellacutelymphoblasticleukemialymphoblasticlymphomatreatmentacasereportandliteraturereview
AT lailamalsuhaibani venetoclaxcombinationwithcladribineidarubicincytarabineforrelapsedtcellacutelymphoblasticleukemialymphoblasticlymphomatreatmentacasereportandliteraturereview
AT bilalalbtoosh venetoclaxcombinationwithcladribineidarubicincytarabineforrelapsedtcellacutelymphoblasticleukemialymphoblasticlymphomatreatmentacasereportandliteraturereview
AT abdullahkhaledalbathi venetoclaxcombinationwithcladribineidarubicincytarabineforrelapsedtcellacutelymphoblasticleukemialymphoblasticlymphomatreatmentacasereportandliteraturereview
AT abdullahmalrajhi venetoclaxcombinationwithcladribineidarubicincytarabineforrelapsedtcellacutelymphoblasticleukemialymphoblasticlymphomatreatmentacasereportandliteraturereview